Sorafenib is a multi-kinase inhibitor approved for hepatocellular carcinoma, but rarely
causes tumor regression in patients with chronic liver diseases. To investigate whether …

Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but
its use is hampered by the occurrence of drug resistance. To investigate the molecular …

Purpose Sorafenib, a multikinase inhibitor, is the standard therapy for patients with
advanced-stage hepatocellular carcinoma (HCC). However, resistance develops to the …

Drug resistance to sorafenib is common in patients with hepatocellular carcinoma (HCC).
We examined the effects of a combination of sorafenib and fluvastatin on HCC using in vitro …

Long‑term sorafenib treatment triggers resistance to chemotherapy in patients with
hepatocellular carcinoma (HCC). In order to investigate the mechanisms of sorafenib …

Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma;
vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit …

Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). Some
patients with HCC initially respond to sorafenib, but eventually succumb to the disease …

Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …

Liver cancer is highly malignant, has a low sensitivity to chemotherapy, and is associated
with poor patient prognosis. The last 3 years have seen the emergence of promising …

Purpose Although sorafenib enhances overall survival, sorafenib resistance has been
reported to be a significant limiting factor for improved prognosis in patients with …